Daraxonrasib, a new pancreatic cancer drug, cut the risk of death by 60% in a Phase 3 trial. A doctor explains how it works, ...
This week on "The Readout LOUD," a pancreatic cancer breakthrough and new hope for an off-the-shelf CAR-T treatment in ...
Senhwa Biosciences raises $16M to advance AI-powered drug discovery, accelerate cancer treatment trials, and expand machine ...
Cancer therapeutics and orphan drugs are no longer niche areas. Specialty drugs are now a significant portion of the prescription drug market, as well as the drug development pipeline, according to a ...
Cancer drug in development at Ohio State could treat some of the most difficult forms of the illness
This weekend, thousands of riders will take to the streets for Pelotonia — the annual bike ride that raises millions of dollars for cancer research right here in Columbus. One of the projects ...
In a difficult disease, Revolution Medicines achieved what the pancreatic cancer community has long desired: a significant improvement in survival. The Phase 3 results will support global regulatory ...
Trastuzumab pamirtecan, being developed under a 2023 partnership between BioNTech and DualityBio, elicited a 44.1% overall ...
The new data bolster Allogene’s efforts to develop a new, easily administered cell therapy that could delay or prevent cancer recurrence.
The protein is implicated in a wide swath of cancers, but harnessing it for drug R&D is still a major scientific challenge.
Merck built a wall of patents that keeps a cancer drug's price – and its profits – high. Hospitals often add to the cost for ...
Merck & Co.'s Keytruda in the U.S. starts at $12,000 for a 200 mg dose. Costs go up from there based on the insurer, provider ...
Many breast cancer drugs block estrogen receptors inside cancer cells. Blocking the receptors early in disease progression staves off metastasis. But most patients with advanced disease eventually ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results